In recent years, CD19-CAR-T therapy has demonstrated significant efficacy in relapsed/refractory DLBCL, particularly showing some penetration into central nervous system lesions, offering new hope for DLBCL patients with central nervous system infiltration (7–10). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.